Steroid hormone receptors in cancer development A target for cancer therapeutics

被引:91
作者
Ahmad, Nihal [2 ]
Kumar, Raj [1 ]
机构
[1] Commonwealth Med Coll, Dept Basic Sci, Scranton, PA 18510 USA
[2] Univ Wisconsin, Dept Dermatol, Madison, WI USA
关键词
Steroid hormone receptor; Glucocorticold; Estrogen; Androgen; Progesterone; Leukemia; Breast cancer; Prostate cancer; Ovarian cancer; HUMAN GLUCOCORTICOID-RECEPTOR; PROSTATE-CANCER; ANDROGEN RECEPTOR; BREAST-CANCER; OVARIAN-CANCER; LIFE-STYLE; MOLECULAR-MECHANISMS; COLORECTAL-CANCER; GENE-EXPRESSION; ESTROGEN ACTION;
D O I
10.1016/j.canlet.2010.09.008
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The steroid hormone receptors (SHRs) are ligand-dependent intracellular transcription factors that are known to influence the development and growth of many human cancers SHRs pass signals from a steroid/hormone to the target genes by interacting with specific response element DNA sequences and various coregulatory proteins that consists of activators and/or corepressors Disruptions in physiological functions of SHRs leads to several types of malignancies such as breast cancer leukemia and lymphoma prostate cancer ovarian cancer and lung cancer among others Steroids/hormones/SHRs and their coregulators have opened up a unique window for novel steroid-based targeted therapies for cancer Thus dysregulation of SHR signaling in cancers compared with normal tissues can be exploited to target drugs that prevent and treat human cancers In recent years hormonal therapy has made a major contribution to the treatment of several cancers including reduced recurrence rates and longer survival rates Development of various steroid receptor modulators and their potential therapeutic efficacies has provided us a great opportunity to effectively manage diseases like cancer in future In this review article we have summarized up-to-date knowledge of the role of SHRs in the development and progression of cancers and potential endocrine-based therapeutic approaches to tackle these diseases (c) 2010 Elsevier Ireland Ltd All rights reserved
引用
收藏
页码:1 / 9
页数:9
相关论文
共 107 条
[91]  
Schneider HPG, 2002, MATURITAS, V43, pS35
[92]  
Schraml P, 1999, CLIN CANCER RES, V5, P1966
[93]  
Scully RE, 1995, J CELL BIOCHEM, P208
[94]  
SRIDHAR G, 2010, AM J MENS HLTH
[95]   Modulation of steroid hormone receptor activity [J].
Stanisic, Vladimir ;
Lonard, David M. ;
O'Malley, Bert W. .
NEUROENDOCRINOLOGY: THE NORMAL NEUROENDOCRINE SYSTEM, 2010, 181 :153-176
[96]   Current Understanding of Risk Factors for Ovarian Cancer [J].
Sueblinvong, Thanasak ;
Carney, Michael E. .
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2009, 10 (1-2) :67-81
[97]   Oestrogen receptor beta (ERβ) polymorphism and its influence on breast cancer risk [J].
Surekha, D. ;
Sailaja, K. ;
Rao, D. Nageswara ;
Raghunadharao, D. ;
Vishnupriya, S. .
JOURNAL OF GENETICS, 2009, 88 (02) :261-266
[98]  
Syed V, 2002, JNCI-J NATL CANCER I, V94, P617
[99]   Analysis of the Molecular Networks in Androgen Dependent and Independent Prostate Cancer Revealed Fragile and Robust Subsystems [J].
Tasseff, Ryan ;
Nayak, Satyaprakash ;
Salim, Saniya ;
Kaushik, Poorvi ;
Rizvi, Noreen ;
Varner, Jeffrey D. .
PLOS ONE, 2010, 5 (01)
[100]   Mechanistic relationship between androgen receptor polyglutamine tract truncation and androgen-dependent transcriptional hyperactivity in prostate cancer cells [J].
Wang, QB ;
Udayakumar, TS ;
Vasaitis, TS ;
Brodie, AM ;
Fondell, JD .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (17) :17319-17328